SuperworthKrystal Biotech price to sales ratio KRYS
Market value divided by revenue over the last twelve months, since 2024.
- Today, Oct 23, 2026
- 20.9×
- 2-year median
- 19.5×
- Against its 2-year history
- 59th
- percentile: 0 is its lowest day, 100 its highest
- 2-year range
- 10.8× to 34.8×
- Peer median
- 6.8×
Krystal Biotech's price to sales ratio is 20.9× as of Oct 23, 2026.
That is above its 2-year median of 19.5×, close to the middle of its last 2 years.
Over that time it ranged from 10.8× in May 2025 to 34.8× in Aug 2024.
The median for 10 biotech stocks of a similar size is 6.8×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 20.9× | 18.4× | 26.5× |
| 2025 | 19.6× | 10.8× | 19.6× |
| 2024 | 19.0× | 19.0× | 34.8× |
Against its peers
Companies in Biotechnology nearest Krystal Biotech's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| KRYSKrystal Biotech | 20.9× |
| RGENRepligen | 12.7× |
| TECHBIO-TECHNE | 9.4× |
| HALOHalozyme Therapeutics | 8.6× |
| NBIXNeurocrine Biosciences | 4.3× |
| EXELExelixis | 6.6× |
| INCYIncyte | 4.0× |
| UTHRUnited Therapeutics | 8.0× |
| ALNYAlnylam Pharmaceuticals | 6.2× |
| ADMAAdma Biologics | 4.7× |
| VCELVericel | 7.1× |
| Peer median | 6.8× |
Where Krystal Biotech ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Krystal Biotech
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.